REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
Resources for patients
and caregivers.
Share these helpful tools and resources with
patients with multiple myeloma and their caregivers.
Treatment Overview
A brochure for patients with
multiple myeloma who have
been prescribed REVLIMID.
Caregiver Brochure
Caregivers can get information and
resources to help them care for
patients with multiple myeloma.
Treatment Calendar
Create a custom treatment calendar to help patients stay organized with treatments/appointments.
AccessFull Prescribing Information
Explore the full Prescribing Information, including Boxed WARNINGS.
DownloadMedication Guide
Read the Medication Guide and help patients understand the potential side effects associated with REVLIMID treatment.
DownloadAdditional resources.

Patient Brochure
A resource for your African American patients living with MM. Download the Standing in the Gaap patient brochure to learn more. These patients can also join the Standing in the Gaap community on Facebook.
Download
Myeloma Central
A website for patients living with MM, offering a Welcome Kit containing treatment calendars, lab test trackers, support, and more.
Visit www.myelomacentral.com.

My Moments, My Support
Encourage patients to sign up for My Moments, My Support to receive a patient starter kit and ongoing education and support.
VisitMM, multiple myeloma.